Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Hyman Carol B. M. D.; Gonick, Harvey C. M. D.; Neufeld, Naomi M. D.; Agness, Cathy L. M. T.
American Journal of Pediatric Hematology/Oncology: Winter 1989
Case Reports: PDF Only

A 12-day balance study with measurements of urine and stool excretion was undertaken to determine the effects of intravenous (i. v.) Desferal (293 mg/kg/24 h x 2) on iron, aluminum, copper, and zinc in a child with Hemoglobin Hammersmith and Turner's syndrome treated as a thalassemia major patient because of symptoms of anemia and ineffective erythropoiesis. Iron balance was positive, 34 mg/3 days baseline. The Desferal infusion induced iron excretion of 117 mg over 48 h, almost equally in stool and urine. This child receives approximately 20 transfusion/i. v. Desferal treatments yearly. If iron excretion is roughly the same with each treatment, it would equal 2,340 mg or 47% of her annual iron intake from transfusion. The i. v. infusions are an important part of this patient's therapy and may also be useful for other chronic transfusion patients for whom subcutaneous Desferal is inadequate for preventing continued iron accumulation. Some patients have successfully received their i. v. Desferal therapy at home, thereby decreasing hospitalization time and cost. Desferal induced moderate aluminum excretion in urine but had no effect on copper or zinc excretion.

© Lippincott-Raven Publishers.